PTGS1 and ovarian adenocarcinoma: Other reports clearly manifested that COX-1 selective inhibitor demonstrated high efficiency toward cyclooxygenase-1 expression of human ovarian adenocarcinoma cells, while celecoxib, a cyclooxygenase-2-selective inhibitor, was inefficacious in either decreasing the biosynthesis of prostaglandin or tumor growth and invasion [27].